Quantinno Capital Management LP Raises Position in United Therapeutics Co. (NASDAQ:UTHR)

Quantinno Capital Management LP raised its stake in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 76.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,311 shares of the biotechnology company's stock after buying an additional 1,003 shares during the quarter. Quantinno Capital Management LP's holdings in United Therapeutics were worth $815,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in UTHR. Newbridge Financial Services Group Inc. purchased a new position in shares of United Therapeutics in the fourth quarter worth $25,000. Dunhill Financial LLC increased its position in United Therapeutics by 100.0% during the fourth quarter. Dunhill Financial LLC now owns 100 shares of the biotechnology company's stock valued at $35,000 after acquiring an additional 50 shares during the last quarter. Millstone Evans Group LLC purchased a new stake in United Therapeutics during the fourth quarter valued at $67,000. MassMutual Private Wealth & Trust FSB increased its position in United Therapeutics by 31.9% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company's stock valued at $85,000 after acquiring an additional 58 shares during the last quarter. Finally, Natixis purchased a new stake in United Therapeutics during the fourth quarter valued at $85,000. Hedge funds and other institutional investors own 94.08% of the company's stock.

Insider Activity at United Therapeutics

In other United Therapeutics news, EVP Paul A. Mahon sold 11,000 shares of the company's stock in a transaction that occurred on Thursday, April 3rd. The stock was sold at an average price of $306.18, for a total transaction of $3,367,980.00. Following the sale, the executive vice president now directly owns 36,781 shares in the company, valued at $11,261,606.58. This represents a 23.02% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, Director Tommy G. Thompson sold 2,500 shares of the company's stock in a transaction that occurred on Monday, March 24th. The shares were sold at an average price of $318.80, for a total value of $797,000.00. Following the sale, the director now owns 8,480 shares in the company, valued at approximately $2,703,424. This trade represents a 22.77% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 45,500 shares of company stock valued at $13,447,180. Insiders own 10.30% of the company's stock.

United Therapeutics Price Performance

Shares of NASDAQ UTHR traded up $1.50 during mid-day trading on Wednesday, reaching $316.34. The company's stock had a trading volume of 272,480 shares, compared to its average volume of 455,330. The firm has a market capitalization of $14.27 billion, a PE ratio of 13.91, a P/E/G ratio of 0.97 and a beta of 0.58. The stock has a fifty day moving average of $299.44 and a two-hundred day moving average of $336.59. United Therapeutics Co. has a 52 week low of $264.33 and a 52 week high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 EPS for the quarter, beating analysts' consensus estimates of $6.29 by $0.34. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The company had revenue of $794.40 million during the quarter, compared to analyst estimates of $726.82 million. During the same period in the prior year, the company earned $6.17 earnings per share. The firm's revenue was up 17.2% on a year-over-year basis. Analysts anticipate that United Therapeutics Co. will post 24.48 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on UTHR shares. Morgan Stanley upped their price objective on United Therapeutics from $346.00 to $348.00 and gave the company an "equal weight" rating in a research report on Thursday, May 1st. JPMorgan Chase & Co. reduced their price target on United Therapeutics from $355.00 to $350.00 and set an "overweight" rating for the company in a research report on Thursday, May 1st. HC Wainwright restated a "buy" rating and issued a $425.00 price target on shares of United Therapeutics in a research report on Monday, May 5th. Wells Fargo & Company restated an "equal weight" rating and issued a $314.00 price target (down previously from $395.00) on shares of United Therapeutics in a research report on Friday, April 25th. Finally, Wall Street Zen cut United Therapeutics from a "strong-buy" rating to a "buy" rating in a research report on Friday, May 2nd. Four investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $392.00.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.